DENVER, Colo. (247marketnews.com) — VivoSim Labs (NASDAQ:VIVS) delivered two developments that could significantly strengthen its investment narrative: a $5 million milestone payment from Eli Lilly tied to a previously divested inflammatory bowel disease drug program, and guidance calling for more than 500% revenue growth in fiscal 2027 as demand accelerates for its human-based preclinical testing platform.
The Lilly payment was triggered by the dosing of the first patient in a Phase 2 clinical trial, validating continued progress of an asset VivoSim previously sold. While Eli Lilly now controls the program, VivoSim remains eligible to receive up to an additional $45 million in milestone payments if future regulatory and commercial objectives are achieved.
More importantly for investors, management believes its core contract research business is reaching an inflection point. The company says pharmaceutical customers are increasingly adopting its three-dimensional human tissue models to improve the prediction of drug safety before expensive clinical trials begin. VivoSim expects this momentum to translate into revenue growth exceeding 500% in FY2027, reflecting expanding commercial adoption rather than a one-time licensing event.
The timing may be especially favorable. The U.S. Food and Drug Administration continues encouraging the use of New Approach Methodologies (NAMs) to reduce reliance on animal testing, creating a potential tailwind for companies offering validated human-relevant alternatives. VivoSim argues its technology is well positioned for this transition, citing internal validation showing its NAMkind
Liver model achieved 91% predictive accuracy, while its intestine models demonstrated greater than 90% sensitivity and overall accuracy in predicting drug-induced diarrhea.
Beyond traditional small-molecule drugs, VivoSim is expanding applications across newer therapeutic modalities including antibody-drug conjugates, antibodies, siRNA therapies, and gene therapies—areas where more predictive safety screening could reduce costly late-stage clinical failures.
While investors should recognize that revenue guidance remains forward-looking and additional Lilly milestones depend on successful clinical, regulatory, and commercial progress, the combination of an immediate cash payment, accelerating commercial adoption, and regulatory support for NAM technologies presents a compelling growth story. If pharmaceutical companies continue shifting toward human-relevant preclinical models, VivoSim could be positioned to benefit from one of the most significant changes in drug development in decades.
Sources
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.